Easier diabetes meds for kids? liquid glibenclamide under study

NCT ID NCT02375828

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 35 times

Summary

This study tested a new liquid version of the drug glibenclamide in 10 children with neonatal diabetes caused by a potassium channel mutation. The goal was to see if the liquid form is easier to give and as safe and effective as the standard pills. Children took the pills for one month, then switched to the liquid for four months, while researchers tracked side effects and how well parents and kids liked the new form.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL DIABETES SECONDARY TO MUTATION IN THE POTASSIUM CHANNEL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hôpital Universitaire Necker Enfants Malades

    Paris, 7501, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

glibenclamide (liquid form)

What this could lead to

If successful, this could provide a child-friendly liquid version of glibenclamide that is easier to give to infants and young children with neonatal diabetes.

What could go wrong

This is a small study with only 10 participants, so results may not apply to all children. The liquid form might not work as well as pills or could cause side effects like low blood sugar.

Conditions

The condition(s) this trial relates to.

neonatal diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.